American Journal of Medicine and Medical Sciences
p-ISSN: 2165-901X e-ISSN: 2165-9036
2011; 1(1): 15-22
doi: 10.5923/j.ajmms.20110101.03
N. M. Abdel-Hamid 1, M. A. Fawzy 1, M. A. El-Moselhy 2
1Biochemistry Department, College of Pharmacy, Minia University, Egypt
2Pharmacology Department, College of Pharmacy, Minia University, Egypt
Correspondence to: N. M. Abdel-Hamid , Biochemistry Department, College of Pharmacy, Minia University, Egypt.
Email: |
Copyright © 2012 Scientific & Academic Publishing. All Rights Reserved.
Objectives: Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. We aimed to test the role of aqueous olive leaf extract (AOLE) in modulating metabolic disorders occurring in hepatic malignancy induced by trichloroacetic acid (TCA). Design: Eight groups of rats were assigned as follows: First, untreated normal control. Second, treated with 5-fluorouracil (5-FU), (75mg/kg), intraperitoneally (IP) once weekly for 3 weeks. Third, treated with oral AOLE (500mg/kg) once daily for 28 days. The 4th group co-treated with AOLE and 5-FU as mentioned above. The 5th group treated with oral daily doses of TCA (500mg/kg) for five days. The 6th group treated with TCA for 5 days, from the sixth day with 5-FU for 3 weeks. Group 7 given TCA then, with AOLE. Group 8 received TCA, 5-FU and AOLE. Blood samples were withdrawn after 28 days from carotid vein. Liver tissues were histologically studied. Results: TCA showed neoplastic tissue features, greatly improved by treatment with AOLE and 5-FU combination. TCA significantly increased blood ALT, AST, alkaline phosphatase (ALP) and acetyl CoA synthase (fatty acid synthase , FAS) activities, total bilirubin (T Bil) , triglycerides (TG), total glycosaminoglycans (TGAGs), alpha-fetoprotein (AFP), reduced serum total lipoprotein lipase (TLPL) activity. AOLE, combined with 5-FU produced a pronounced improvement in most of studied parameters. Conclusion: AOLE showed promising hepatoprotective and adjuvant anticancer properties if combined with 5-FU.
Keywords: HCC, 5-FU, Olive Leaves, Acyl Co Synthase, Lipase, Adjuvant Herbal
Cite this paper: N. M. Abdel-Hamid , M. A. Fawzy , M. A. El-Moselhy , "Evaluation of Hepatoprotective and Anticancer Properties of Aqueous Olive Leaf Extract in Chemically Induced Hepatocellular Carcinoma in Rats", American Journal of Medicine and Medical Sciences, Vol. 1 No. 1, 2011, pp. 15-22. doi: 10.5923/j.ajmms.20110101.03.
Figure 1. Liver section in control animals showing normal parenchymal cells with granulated cytoplasm and normal architecture |
Figure 2. TCA-treated rats showing loss of normal architecture with oval- or irregular-shaped hepatocytes, denser nuclear chromatin, the ratio of nucleus to cytoplasm was increased, many transformed liver cells were frequently binucleated and hyperchromatic (basophilic) |
Figure 3. The liver of 5-FU-treated rats showing normal central vein and architecture, some liver cells around central vein showed ballooning that may be due to cyotoxic effect of 5-FU |
Figure 4. Liver section in TCA and 5-FU treated rats showing reversed changes as central vein congestion and ballooning but generally is less than TCA-treated group indicating some improvement |
Figure 5. Liver section in AOLE-treated rats shows a normal central vein and blood sinusoids |
Figure 6. Liver section in TCA and AOLE treated rats showing a moderate improvement in hepatocellular structure, evidenced as a moderate improvement in vacuolation and compactness of hepatocytes compared to TCA treated group but dilated sinusoids are still present |
Figure7. Liver section in 5-FU and AOLE-treated rats shows a normal pattern of healthy hepatocytes |
Figure 8. Liver section in TCA, 5-FU and AOLE-treated rats showed almost normal hepatocytes with small degree of central vein congestion as the cellular architecture of liver sections in this group seemed to be almost comparable to that of their normal counterparts. |
[1] | W. Y. Lau, Management of hepatocellular carcinoma. J R Coll Surg Edinb 47 (2002) 389-99 |
[2] | T. A. Ahles, A. J. Saykin, C. T. Furstenberg, B. Cole, L. A. Mott, K. Skalla, M. B. Whedon, S. Bivens, T. Mitchell, E. R. Greenberg, and P. M. Silberfarb, Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20 (2002) 485-93 |
[3] | H. M. Cheng, and M. C. Tsai, Regression of hepatocellular carcinoma spontaneous or herbal medicine related? Am J Chin Med 32 (2004) 579-85 |
[4] | Raymond M. Hozalski, William A. Arnold, , Chanlan Chun, Timothy M. LaPara, Jeong-Yub Lee, Carrie R. Pearson, and , Ping Zhang, Degradation of Halogenated Disinfection Byproducts in Water Distribution Systems., ACS Symposium Series, USA, 2008 |
[5] | H. J. Clewell, and M. E. Andersen, Applying mode-of-action and pharmacokinetic considerations in contemporary cancer risk assessments: an example with trichloroethylene. Crit Rev Toxicol 34 (2004) 385-445 |
[6] | R. Lumaret, and N. Ouazzani, Plant genetics. Ancient wild olives in Mediterranean forests. Nature 413 (2001) 700 |
[7] | E. Waterman, and B. Lockwood, Active components and clinical applications of olive oil. Altern Med Rev 12 (2007) 331-42 |
[8] | F. Visioli, A. Poli, and C. Gall, Antioxidant and other biological activities of phenols from olives and olive oil. Med Res Rev 22 (2002) 65-75 |
[9] | R. Fabiani, A. De Bartolomeo, P. Rosignoli, M. Servili, G. F. Montedoro, and G. Morozzi, Cancer chemoprevention by hydroxytyrosol isolated from virgin olive oil through G1 cell cycle arrest and apoptosis. Eur J Cancer Prev 11 (2002) 351-8 |
[10] | H. K. Hamdi, and R. Castellon, Oleuropein, a non-toxic olive iridoid, is an anti-tumor agent and cytoskeleton disruptor. Biochem Biophys Res Commun 334 (2005) 769-78 |
[11] | R. W. Owen, A. Giacosa, W. E. Hull, R. Haubner, B. Spiegelhalder, and H. Bartsch, The antioxidant/anticancer potential of phenolic compounds isolated from olive oil. Eur J Cancer 36 (2000) 1235-47 |
[12] | M. Kaibori, Y. Matsui, H. Yanagida, N. Yokoigawa, A. H. Kwon, and Y. Kamiyama, Positive status of alpha-fetoprotein and des-gamma-carboxy prothrombin: important prognostic factor for recurrent hepatocellular carcinoma. World J Surg 28 (2004) 702-7 |
[13] | A. S. Befeler, and A. M. Di Bisceglie, Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 122 (2002) 1609-19 |
[14] | P. L. Alo, P. Visca, A. Marci, A. Mangoni, C. Botti, and U. Di Tondo, Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 77 (1996) 474-82 |
[15] | P. L. Alo, P. Visca, G. Trombetta, A. Mangoni, L. Lenti, S. Monaco, C. Botti, D. E. Serpieri, and U. Di Tondo, Fatty acid synthase (FAS) predictive strength in poorly differentiated early breast carcinomas. Tumori 85 (1999) 35-40 |
[16] | Y. Wang, F. P. Kuhajda, J. N. Li, E.S. Pizer, W. F. Han, L. J. Sokoll, and D. W. Chan, Fatty acid synthase (FAS) expression in human breast cancer cell culture supernatants and in breast cancer patients. Cancer Lett 167 (2001) 99-104 |
[17] | A. Rashid, E. S. Pizer, M. Moga, L. Z. Milgraum, M. Zahurak, G. R. Pasternack, F. P. Kuhajda, and S. R. Hamilton, Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am J Pathol 150 (1997) 201-8 |
[18] | M. S. Shurbaji, J. H. Kalbfleisch, and T. S. Thurmond, Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer. Hum Pathol 27 (1996) 917-21 |
[19] | T. S. Gansler, W. Hardman, 3rd, D. A. Hunt, S. Schaffel, and R.A. Hennigar, Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol 28 (1997) 686-92 |
[20] | E. S. Pizer, S. F. Lax, F. P. Kuhajda, G. R. Pasternack, and R. J. Kurman, Fatty acid synthase expression in endometrial carcinoma: correlation with cell proliferation and hormone receptors. Cancer 83 (1998) 528-37 |
[21] | J. R. Mead, S. A. Irvine, and D. P. Ramji, Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med 80 (2002) 753-69 |
[22] | R. W. Clark, and R. C. Crain, Characterization of Alterations in Plasma Lipoprotein Lipid and Apoprotein Profiles Accompanying Hepatoma-Induced Hyperlipidemia in Rats. Cancer Res 46 (1986) 1894-1903 |
[23] | R. D. Sanderson, Y. Yang, L. J. Suva, and T. Kelly, Heparan sulfate proteoglycans and heparanase--partners in osteolytic tumor growth and metastasis. Matrix Biol 23 (2004) 341-52 |
[24] | N. M. Abdel-Hamid, Recent insights on risk factors of hepatocellular carcinoma. World J Hepatol 1 (2009) 3-7 |
[25] | N. M. Abdel-Hamid, and M. A. Morsy, Novel biochemical pathways for 5-Fluorouracil in managing experimental hepatocellular carcinoma in rats. J Membr Biol 234 (2010) 29-34 |
[26] | E. J. Joo, G. B. ten Dam, T. H. van Kuppevelt, T. Toida, R. J. Linhardt, and Y. S. Kim, Nucleolin: acharan sulfate-binding protein on the surface of cancer cells. Glycobiology 15 (2005) 1-9 |
[27] | G. Milano, and A. L. Chamorey, Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharm- acokinetics. Chronobiol Int 19 (2002) 177-89 |
[28] | M. Y. Hung, T. Y. Fu, P. H. Shih, C. P. Lee, and G. C. Yen, Du-Zhong (Eucommia ulmoides Oliv.) leaves inhibits CCl4-induced hepatic damage in rats. Food Chem Toxicol 44 (2006) 1424-31 |
[29] | C. M. Bender, S. M. Sereika, S. L. Berga, V. G. Vogel, A. M. Brufsky, K. K. Paraska, and C. M. Ryan, Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology 15 (2006) 422-30 |
[30] | G. Winocur, J. Vardy, M. A. Binns, L. Kerr, and I. Tannock, The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice. Pharmacol Biochem Behav 85 (2006) 66-75 |
[31] | L. Tao, S. Yang, M. Xie, P. M. Kramer, and M. A. Pereira, Effect of trichloroethylene and its metabolites, dichloroacetic acid and trichloroacetic acid, on the methylation and expression of c-Jun and c-Myc protooncogenes in mouse liver: prevention by methionine. Toxicol Sci 54 (2000) 399-407 |
[32] | S. R. Channel, J. R. Latendresse, J. K. Kidney, J. H. Grabau, J. W. Lane, L. Steel-Goodwin, and M.C. Gothaus, A subchronic exposure to trichloroethylene causes lipid peroxidation and hepatocellular proliferation in male B6C3F1 mouse liver. Toxicol Sci 43 (1998) 145-54 |
[33] | C. Dees, and C. Travis, Trichloroacetate stimulation of liver DNA synthesis in male and female mice. Toxicol Lett 70 (1994) 343-55 |
[34] | J. L. Larson, and R. J. Bull, Metabolism and lipoperoxidative activity of trichloroacetate and dichloroacetate in rats and mice. Toxicol Appl Pharmacol 115 (1992) 268-77 |
[35] | J. A. Styles, I. Wyatt, and C. Coutts, Trichloroacetic acid: studies on uptake and effects on hepatic DNA and liver growth in mouse. Carcinogenesis 12 (1991) 1715-9 |
[36] | S. Rietman, and S. Frankle, A Colorimetric Method for Determination of Serum Glutamic Oxaloacetic and Glutamic Pyruvic Transaminases. Am. J. Clin. Path 28 (1957) |
[37] | N. Gond, and S. Khadabadi, Hepatoprotective activity of Ficus carica leaf extract on rifampicin-induced hepatic damage in rats. Indian J Pharm Sci 70 (2008) 364-6 |
[38] | A. Belfield, and D.M. Goldberg, Revised assay for serum phenyl phosphatase activity using 4-amino-antipyrine. Enzyme 12 (1971) 561-73 |
[39] | L. Jendrassik, and P. Grof, Biochem. J 297 (1938) 81 |
[40] | P. J. Bosma, J. R. Chowdhury, C. Bakker, S. Gantla, A. de Boer, B. A. Oostra, D. Lindhout, G. N. Tytgat, P. L. Jansen, R. P. Oude Elferink, and et al., The genetic basis of the reduced expression of bilirubin UDP-glucuronosyl- transferase 1 in Gilbert's syndrome. N Engl J Med 333 (1995) 1171-5 |
[41] | E. W. Gold, A simple spectrophotometric method for estimating glycosaminoglycan concentrations. Anal Biochem 99 (1979) 183-8. |
[42] | N. J. Jacobs, and P. J. Vandemark, The purification and properties of the alpha-glycerophosphate-oxidizing enzyme of Streptococcus faecalis 10C1. Arch Biochem Biophys 88 (1960) 250-5. |
[43] | P. Trinder, Enzymatic Calorimetric Test Clin. Biochem. J 6 (1969) 24-27. |
[44] | N. W. Tietz, Textbook of Clinical Chemistry. W. B. Saunders CO Philadelphia (1999) |
[45] | D. S. Young, Effect of Drugs on Clinical Lab Test. 5th Ed. AACC press (2000) |
[46] | G. I. Abelev, Alpha-fetoprotein as a marker of embryo-specific differentiations in normal and tumor tissues. Transplant Rev 20 (1974) 3-37 |
[47] | D. W. Chan, and Y. C. Miao, Affinity chromatographic separation of alpha-fetoprotein variants: development of a mini-column procedure, and application to cancer patients. Clin Chem 32 (1986) 2143-6 |
[48] | M. Uotila, E. Ruoslahti, and E. Engvall, Two-site sandwich enzyme immunoassay with monoclonal antibodies to human alpha-fetoprotein. J Immunol Methods 42 (1981) 11-5 |
[49] | Y. Kuang, N. Salem, F. Wang, S. J. Schomisch, V. Chandramouli, and Z. Lee, A colorimetric assay method to measure acetyl-CoA synthetase activity: application to woodchuck model of hepatitis virus-induced hepatocellular carcinoma. J Biochem Biophys Methods 70 (2007) 649-55 |
[50] | M. C. Kew, Serum aminotransferase concentration as evidence of hepatocellular damage. Lancet 355 (2000) 591-2 |
[51] | T. W. Leung, A. M. Tang, B. Zee, S. C. Yu, P. B. Lai, W. Y. Lau, and P. J. Johnson, Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 94 (2002) 421-7 |
[52] | D. V. Gopal, and H. R. Rosen, Abnormal findings on liver function tests. Interpreting results to narrow the diagnosis and establish a prognosis. Postgrad Med 107 (2000) 100-2, 105-9, 113-4 |
[53] | W. Yeo, F. K. Mo, J. Koh, A. T. Chan, T. Leung, P. Hui, L. Chan, A. Tang, J. J. Lee, T. S. Mok, P. B. Lai, P. J. Johnson, and B. Zee, Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Ann Oncol 17 (2006) 1083-9 |
[54] | W. Yeo, T. S. Mok, B. Zee, T. W. Leung, P. B. Lai, W. Y. Lau, J. Koh, F. K. Mo, S. C. Yu, A. T. Chan, P. Hui, B. Ma, K. C. Lam, W. M. Ho, H. T. Wong, A. Tang, and P. J. Johnson, A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97 (2005) 1532-8 |
[55] | G. Zhang, Y. Miura, and K. Yagasaki, Effects of dietary powdered green tea and theanine on tumor growth and endogenous hyperlipidemia in hepatoma-bearing rats. Biosci Biotechnol Biochem 66 (2002) 711-6 |
[56] | G. Muralikrishnan, V. Amalan Stanley, and K. Sadasivan Pillai, Dual role of vitamin C on lipid profile and combined application of cyclophosphamide, methotrexate and 5-fluorouracil treatment in fibrosarcoma-bearing rats. Cancer Lett 169 (2001) 115-20 |
[57] | S. Subramaniam, S. Subramaniam, and C. S. Shyamala Devi, Erythrocyte antioxidant enzyme activity in CMF treated breast cancer patients. Cancer Biochem Biophys 14 (1994) 177-82 |
[58] | S. Acin, M. A. Navarro, J. S. Perona, J. M. Arbones-Mainar, J. C. Surra, M. A. Guzman, R. Carnicer, C. Arnal, I. Orman, J. C. Segovia, J. Osada, and V. Ruiz-Gutierrez, Olive oil preparation determines the atherosclerotic protection in apolipoprotein E knockout mice. J Nutr Biochem 18 (2007) 418-24 |
[59] | M. Kawasaki, R. Funabiki, and K. Yagasaki, Effects of dietary methionine and cystine on lipid metabolism in hepatoma-bearing rats with hyperlipidemia. Lipids 33 (1998) 905-11 |
[60] | G. W. Yip, M. Smollich, and M. Gotte, Therapeutic value of glycosaminoglycans in cancer. Mol Cancer Ther 5 (2006) 2139-48 |
[61] | S. S. Skandalis, M. Stylianou, D. H. Vynios, N. Papageorgakopoulou, and D. A. Theocharis, The structural and compositional changes of glycosaminoglycans are closely associated with tissue type in human laryngeal cancer. Biochimie 89 (2007) 1573-80 |
[62] | L. X. Qin, and Z. Y. Tang, Metastasis and Recurrence after Surgical Resection of Hepatocellular Recent Progress in Clinical and Related Basic Aspects Carcinoma. Current Cancer Therapy Reviews 1 (2005) 71-80 |
[63] | L. P. Borges, V. C. Borges, A. V. Moro, C. W. Nogueira, J. B. Rocha, and G. Zeni, Protective effect of diphenyl diselenide on acute liver damage induced by 2-nitropropane in rats. Toxicology 210 (2005) 1-8 |
[64] | B. Premalatha, and P. Sachdanandam, Effect of Semecarpus Anacardium Nut Milk Extract on Rat Serum Alpha-Fetoprotein Level in Aflatoxin B -Mediated Hepatocellular Carcinoma. Fitoterapia 70 (1999) 279-283 |
[65] | N. Yahagi, H. Shimano, K. Hasegawa, K. Ohashi, T. Matsuzaka, Y. Najima, M. Sekiya, S. Tomita, H. Okazaki, Y. Tamura, Y. Iizuka, K. Ohashi, R. Nagai, S. Ishibashi, T. Kadowaki, M. Makuuchi, S. Ohnishi, J. Osuga, and N. Yamada, Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma. Eur J Cancer 41 (2005) 1316-22 |
[66] | C. Peraino, E. F. Staffeldt, and V. A. Ludeman, Early appearance of histochemically altered hepatocyte foci and liver tumors in female rats treated with carcinogens one day after birth. Carcinogenesis 2 (1981) 463-5 |